ObsEva
ObsEva
  • Home
  • Our Science
    • ART
    • Uterine Fibroids
    • Endometriosis
    • Preterm Labor
    • Obseva Publications
  • Our Pipeline
    • Overview
    • Nolasiban
    • Linzagolix
    • OBE022
  • Partnering
  • Investors
    • Company Profile
    • Financial Reports
    • Stock Data
    • SEC Filings
    • Corporate Governance
    • Event Calendar
    • General Meetings
    • Press Releases
    • Sign Up For News
  • Our Company
    • Work With Us
    • Leadership Team
    • Scientific Advisory Board
  • PR – ObsEva Publications – Media – Events
    • Press Releases
    • Obseva Publications
    • Media
    • Events
  • Contact
Skip to content
  • Our Company
    • Work With Us
    • Leadership Team
    • Scientific Advisory Board
  • PR – ObsEva Publications – Media – Events
    • Press Releases
    • Obseva Publications
    • Media
    • Events
  • Contact
Skip to content
ObsEva
  • Home
  • Our Science
    • ART
    • Uterine Fibroids
    • Endometriosis
    • Preterm Labor
    • Obseva Publications
  • Our Pipeline
    • Overview
    • Nolasiban
    • Linzagolix
    • OBE022
  • Partnering
  • Investors
    • Company Profile
    • Financial Reports
    • Stock Data
    • SEC Filings
    • Corporate Governance
    • Event Calendar
    • General meetings
    • Press Releases
    • Sign Up For News

Month: September 2019

ObsEva SA to Participate in Cantor Global Healthcare Conference October 2-4, 2019

Posted on September 27, 2019 (September 26, 2019) by Shauna Dillon

Geneva, Switzerland and Boston, MA – September 27, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…

Posted in Content, Press releaseTagged 2019Leave a comment

ObsEva announces new composition of its Executive Committee

Posted on September 11, 2019 (September 11, 2019) by Shauna Dillon

Geneva, Switzerland and Boston, MA – September 11, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…

Posted in Content, Press releaseTagged 2019Leave a comment

The H.C. Wainwright 21st Annual Global Investment in NYC – September 10th 2019

Posted on September 10, 2019 (September 18, 2019) by Shauna Dillon
Posted in company profile, Investor Presentations, Page blockTagged presentationLeave a comment

ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF

Posted on September 3, 2019 (September 2, 2019) by Shauna Dillon

Results show decreased uterine contractions, increased endometrial blood flow and gene expression relevant for uterine receptivity to implantation 4Q:19 Read-out…

Posted in Content, Press releaseTagged 2019Leave a comment

Recent Posts

  • ObsEva to participate in The 10th Annual Jefferies Global Healthcare Conference, November 20-21, 2019
  • Investor Presentation 10th Annual Jefferies Global Healthcare Conference 21 November 2019
  • ObsEva to participate in The Credit Suisse Healthcare Conference, November 11-13, 2019
  • Investor Presentation November 2019
  • Third Quarter 2019 Financial Results 7 November 2019

Recent Comments

    Archives

    • November 2019
    • October 2019
    • September 2019
    • August 2019
    • July 2019
    • June 2019
    • May 2019
    • April 2019
    • March 2019
    • February 2019
    • January 2019
    • December 2018
    • November 2018
    • October 2018
    • September 2018
    • August 2018
    • July 2018
    • June 2018
    • May 2018
    • April 2018
    • March 2018
    • February 2018
    • January 2018
    • December 2017
    • November 2017
    • October 2017
    • September 2017
    • August 2017
    • July 2017
    • June 2017
    • May 2017
    • April 2017
    • March 2017
    • February 2017
    • January 2017
    • October 2016
    • August 2016
    • July 2016
    • May 2016
    • April 2016
    • March 2016
    • November 2015
    • October 2015
    • September 2015
    • June 2015
    • March 2015
    • February 2015
    • November 2014
    • September 2014
    • July 2014
    • January 2014
    • August 2013
    • January 2000

    Categories

    • ART
    • Board of Directors
    • Clinical studies
    • Committee
    • company profile
    • Contact
    • Content
    • Corporate governance
    • Endometriosis
    • event calendar
    • event form
    • Events
    • Financial Report
    • Governance Documents
    • homepage
    • Interview with Ernest Loumaye
    • Investor Presentations
    • Investors landingpage
    • Leadership Team
    • Linzagolix
    • Media
    • Nolasiban
    • OBE022
    • ObsEva General Meetings
    • Our pipeline overview
    • Page block
    • Partnering
    • Press release
    • Preterm Labor
    • privacy policy
    • Publications
    • Scientific Advisory Board
    • Sign up for news
    • Terms
    • Uterine Fibroids
    • Work with us

    Meta

    • Log in
    • Entries RSS
    • Comments RSS
    • WordPress.org
     
    • Our Science
    • Our Pipeline
    • Partnering
    • Investors
    • Our Company
    • ObsEva Publications
    • Press Releases
    • Contact: 

    Follow us on LinkedIn

    Sign up for news

    Copyright © 2019 ObsEva - All rights reserved.

    Terms - Privacy Policy